Published on
February 17, 2026
- 16:00 GMT
Abalone Bio & Mount Sinai Researchers Publish Preclinical Data on First CB2 Antibody Agonists in Molecular Pharmacology
Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone Bio’s FAST Platform EMERYVILLE, CA, UNITED STATES, February 17, 2026 /EINPresswire.com/ -- Abalone Bio, the only antibody drug company …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Science
...
